Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from BCAL Diagnostics Limited ( (AU:BDX) ).
BCAL Diagnostics has completed preparations for the Australian launch of its Avantect blood tests for pancreatic and ovarian cancer, with initial availability from 19 January 2026 in Sydney and a national rollout planned later in the year, targeting high‑risk patients who currently lack effective early detection options. The company is also expanding the clinical and commercial footprint of its BREASTESTplus blood test for women with dense breast tissue, supported by new Australian study data showing high sensitivity and a strong negative predictive value, and by national ethics approval to establish a registry of up to 24,000 women that is expected to underpin wider clinician adoption and potential reimbursement pathways; financially, BCAL ended the quarter with $3.3 million in cash, added a $10 million convertible note facility with $3 million drawn, received a $2.5 million R&D tax refund, and is now focused on revenue generation and market awareness following the launch of its new cancer tests.
The most recent analyst rating on (AU:BDX) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on BCAL Diagnostics Limited stock, see the AU:BDX Stock Forecast page.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is an Australian healthcare company focused on early cancer detection, developing and commercialising blood-based diagnostic tests primarily targeting breast, pancreatic and ovarian cancers, with an emphasis on high-risk patient groups and improving clinical decision-making in oncology care.
Average Trading Volume: 492,072
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$47.85M
See more insights into BDX stock on TipRanks’ Stock Analysis page.